1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | DMS-273; DMS273 |
| Species | Human |
| Cat.No | ABC-TC0214 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Pleural Fluid |
| Disease | Lung Small Cell Cancer |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Lung Cancer Cell Lines |
DMS-273 is a small-cell lung cancer(SCLC) cell line isolated from the pleural effusion of a patient with small-cell carcinoma of the lung. It harbors a p53 mutation at G245C. DMS-273 cells exhibit intercellular processes and express mRNA and protein associated with retinoblastoma. Furthermore, DMS-273 has been observed to exhibit tumorigenicity in nude mice. The expression of hepatocyte growth factor (HGF) and its receptor, receptor tyrosine kinase (RTK) MET, has also been detected in DMS-273 cells.
Why choose DMS 273 from AcceGen?
AcceGen supports DMS-273 with the highest viability. DMS-273 is tested with the comprehensive and standardized procedures of quality control, including the cell product’s impeccable sterility, high viability, confirmed identity, and growth assessment to make it a reliable and advantageous tool for a wide range of scientific investigations.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
DMS-273 is a valuable cell line for studying small-cell lung cancer (SCLC), an aggressive cancer known for its high metastatic potential. The transplantation of DMS-273 into the lungs of nude mice enables the establishment of a metastasis model and facilitates the testing of drugs or inhibitors. For instance, DMS-273 exhibits amplification of the SETDB1 gene, resulting in the overexpression of SETDB1 protein, which enhances cell invasion in lung carcinoma. This finding provides insights into the potential application of SETDB1 inhibitors as new therapies. Similarly, in DMS-273, inhibitors or siRNA targeting signaling pathways associated with cancer progression and invasion can be tested to impede the progression of SCLC.
